Olema Pharmaceuticals Inc (OLMA)

Currency in USD
5.31
+0.74(+16.19%)
Closed·
5.39+0.08(+1.51%)
·
OLMA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Unusual trading volume
OLMA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.915.58
52 wk Range
2.8613.93
Key Statistics
Prev. Close
5.31
Open
4.93
Day's Range
4.91-5.58
52 wk Range
2.86-13.93
Volume
1.4M
Average Volume (3m)
695.32K
1-Year Change
-56.48%
Book Value / Share
5.61
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
OLMA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
24.71
Upside
+365.43%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Olema Pharmaceuticals Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Olema Pharmaceuticals Inc Company Profile

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Compare OLMA to Peers and Sector

Metrics to compare
OLMA
Peers
Sector
Relationship
P/E Ratio
−2.8x−3.2x−0.5x
PEG Ratio
−0.73−0.010.00
Price/Book
0.9x2.6x2.6x
Price / LTM Sales
-8.7x3.3x
Upside (Analyst Target)
-196.4%41.6%
Fair Value Upside
Unlock8.1%5.9%Unlock

Analyst Ratings

8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 24.71
(+365.43% Upside)

Earnings

Latest Release
Aug 11, 2025
EPS / Forecast
-0.51 / -0.38
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

OLMA Income Statement

People Also Watch

2.630
VTYX
-0.38%
14.98
OSCR
-4.04%
28.70
OUST
+2.94%
1.790
CRBU
+4.68%

FAQ

What Stock Exchange Does Olema Trade On?

Olema is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Olema?

The stock symbol for Olema is "OLMA."

What Is the Olema Market Cap?

As of today, Olema market cap is 363.32M.

What Is Olema's Earnings Per Share (TTM)?

The Olema EPS (TTM) is -1.95.

When Is the Next Olema Earnings Date?

Olema will release its next earnings report on 10 Nov 2025.

From a Technical Analysis Perspective, Is OLMA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Olema Stock Split?

Olema has split 0 times.

How Many Employees Does Olema Have?

Olema has 102 employees.

What is the current trading status of Olema (OLMA)?

As of 13 Aug 2025, Olema (OLMA) is trading at a price of 5.31, with a previous close of 5.31. The stock has fluctuated within a day range of 4.91 to 5.58, while its 52-week range spans from 2.86 to 13.93.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.